Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBT Margin (2023 - 2025)

Historic EBT Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to 138.85%.

  • Iovance Biotherapeutics' EBT Margin rose 64200.0% to 138.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 159.06%, marking a year-over-year increase of 2989500.0%. This contributed to the annual value of 228.56% for FY2024, which is 374094500.0% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported EBT Margin of 138.85% as of Q3 2025, which was up 64200.0% from 182.93% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' EBT Margin registered a high of 104.49% during Q4 2024, and its lowest value of 44960.08% during Q2 2023.
  • For the 3-year period, Iovance Biotherapeutics' EBT Margin averaged around 11111.63%, with its median value being 278.04% (2024).
  • In the last 5 years, Iovance Biotherapeutics' EBT Margin surged by 446432400bps in 2024 and then surged by 64200bps in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' EBT Margin stood at 24509.96% in 2023, then surged by 100bps to 104.49% in 2024, then crashed by -33bps to 138.85% in 2025.
  • Its last three reported values are 138.85% in Q3 2025, 182.93% for Q2 2025, and 239.24% during Q1 2025.